Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
08:00am, Thursday, 02'nd May 2024
PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
12:17pm, Wednesday, 27'th Mar 2024
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
07:30am, Wednesday, 27'th Mar 2024
Unique mechanism of action of the combination of PDS01ADC and Versamune ® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
08:00am, Wednesday, 20'th Mar 2024
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing p
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
10:55am, Wednesday, 13'th Mar 2024
Biotech stocks are not for investors with a low-risk tolerance. This sector has stocks that are either considered blue-chip names or pre-revenue lotto tickets.
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
08:00am, Wednesday, 13'th Mar 2024
Preclinical research published in Vaccines demonstrates Infectimune ® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants
PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data
06:59pm, Friday, 26'th Jan 2024
Preliminary efficacy results from phase 1/2 Mayo Clinic study, using PDS0101 + KEYTRUDA to treat patients with Oropharyngeal cancer, expected in Q2 2024. The global oral cancer treatment market is exp
PDS Biotech Announces Retirement of Lauren V. Wood, M.D.
04:45pm, Monday, 22'nd Jan 2024
Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company Board-certified oncologist and hemat
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
08:00am, Tuesday, 16'th Jan 2024
PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pi
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
01:32pm, Tuesday, 02'nd Jan 2024
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:50pm, Monday, 04'th Dec 2023
PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeli
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
07:30am, Tuesday, 28'th Nov 2023
PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pi
PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript
12:17pm, Tuesday, 14'th Nov 2023
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Nicole Jones - Investor Relations Frank Bedu-Addo - Chief Executive Offi
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
07:30am, Tuesday, 14'th Nov 2023
PRINCETON, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pi
